Portopulmonary hypertension

References

• Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363:1461–1468.
   PubMed Web of Science ®Google Scholar
• Machicao VI, Balakrishnan M, Fallon MB. Pulmonary complications in chronic liver disease. Hepatology. 2014;59:1627–1637.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Roisin R, Krowka MJ, Herve P, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24:861–880.
   PubMed Web of Science ®Google Scholar
• Porres-Aguilar M, Mukherjee D. Portopulmonary hypertension: an update. Respirology. 2015;20:235–242.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Krowka MJ. Portopulmonary hypertension. Clin Liver Dis. 2014;18:421–438.
   PubMed Web of Science ®Google Scholar
• Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transpl. 2012;18:881–891.
   PubMed Web of Science ®Google Scholar
• Rodriquez-Roisin R, Krowka MJ, Herve P, et al. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). J Hepatol. 2005;42:924–927.
   PubMed Web of Science ®Google Scholar
• Mantz FJ, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol. 1951;52:91–97.
   PubMedGoogle Scholar
• Lebrec D, Capron JP, Dhumeaux D, et al. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis. 1979;120:849–856.
   PubMed Web of Science ®Google Scholar
• Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11:1153–1166.
   PubMed Web of Science ®Google Scholar
• Herve P, Le Pavec J, Sztrymf B, et al. Pulmonary vascular abnormalities in cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21:141–159.
   PubMed Web of Science ®Google Scholar
• Porres-Aguilar M, Gallegos-Orozco JF, Garcia H, et al. Pulmonary vascular complications in portal hypertension and liver disease: a concise review. Rev Gastroenterol Mex. 2013;78:35–44.
   PubMedGoogle Scholar
• Fritz JS, Fallon MB, Kawut SM. Pulmonary vascular complications of liver disease. Am J Respir Crit Care Med. 2013;187:133–143.
   PubMed Web of Science ®Google Scholar
• Horvatits T, Fuhrmann V. Therapeutic options in pulmonary hepatic vascular diseases. Expert Rev Clin Pharmacol. 2014;7:31–42.
   PubMed Web of Science ®Google Scholar
• Al-Harbi A, Abdullah K, Al-Abdulkareem A, et al. Prevalence of portopulmonary hypertension among liver transplant candidates in a region highly endemic for viral hepatitis. Ann Transplant. 2014;19:1–5.
   PubMed Web of Science ®Google Scholar
• Chen HS, Xing SR, Xu WG, et al. Portopulmonary hypertension in cirrhotic patients: prevalence, clinical features and risk factors. Exp Ther Med. 2013;5:819–824.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology. 2006;44:1502–1510.
   PubMed Web of Science ®Google Scholar
• Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl. 2013;19:602–610.
   PubMed Web of Science ®Google Scholar
• Cotton CL, Gandhi S, Vaitkus PT, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl. 2002;8:1051–1054.
   PubMed Web of Science ®Google Scholar
• Colle I. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology. 2003;37:401–409.
   PubMed Web of Science ®Google Scholar
• Perkins JD. Screening for portopulmonary hypertension. Liver Transpl. 2007;13:463–464.
   PubMed Web of Science ®Google Scholar
• Farzaneh-Far R, McKeown BH, Dang D, et al. Accuracy of Doppler-estimated pulmonary vascular resistance in patients before liver transplantation. Am J Cardiol. 2008;101:259–262.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012;141:906–915.
   PubMed Web of Science ®Google Scholar
• Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol. 2001;36:181–186.
   PubMed Web of Science ®Google Scholar
• Ghayumi SM, Mehrabi S, Zamirian M, et al. Pulmonary complications in cirrhotic candidates for liver transplantation. Hepat Mon. 2010;10:105–109.
   PubMed Web of Science ®Google Scholar
• Gayathri AP, Jaya DR, Anjali AD, et al. Portopulmonary hypertension in a case of non-cirrhotic portal fibrosis. Indian J Pathol Microbiol. 2007;50:828–830.
   PubMedGoogle Scholar
• Kobayashi D, Edwards HD, Singh J, et al. Portopulmonary hypertension secondary to congenital extrahepatic portosystemic shunt with heterotaxy and polysplenia: a cause of sudden death in an infant. Pediatr Pulmonol. 2011;46:1041–1044.
   PubMed Web of Science ®Google Scholar
• Saunders JB, Constable TJ, Heath D, et al. Pulmonary hypertension complicating portal vein thrombosis. Thorax. 1979;34:281–283.
   PubMed Web of Science ®Google Scholar
• Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48:196–203.
   PubMed Web of Science ®Google Scholar
• Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123:562–576.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, McGoon MD. Portopulmonary hypertension: the next step. Chest. 1997;112:869–870.
   PubMed Web of Science ®Google Scholar
• Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, et al. Portopulmonary hypertension: state of the art. Ann Hepatol. 2008;7:321–330.
   PubMed Web of Science ®Google Scholar
• Fallon MB. Portopulmonary hypertension: mew clinical insights and more questions on pathogenesis. Hepatology. 2003;37:253–255.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Edwards WD. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl. 2000;6:241–242.
   PubMed Web of Science ®Google Scholar
• Feltracco P, Serra E, Brezzi ML, et al. Hemodynamic profile of portopulmonary hypertension. Transplant Proc. 2009;41:1235–1239.
   PubMed Web of Science ®Google Scholar
• Yeshua H, Blendis LM, Oren R. Pulmonary manifestations of liver diseases. Sem Cardiothoracic Vasc Anesth. 2009;13:60–69.
   PubMedGoogle Scholar
• Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest. 1997;112:980–986.
   PubMed Web of Science ®Google Scholar
• Raevens S, Geerts A, Van Steenkiste C, et al. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int. 2015;35:1646–1660.
   PubMed Web of Science ®Google Scholar
• Jones FD, Kuo PC, Johnson LB, et al. The coexistence of portopulmonary hypertension and hepatopulmonary syndrome. Anesthesiology. 1999;90:626–629.
   PubMed Web of Science ®Google Scholar
• Ioachimescu OC, Mehta AC, Stoller JK. Hepatopulmonary syndrome following portopulmonary hypertension. Eur Respir J. 2007;29:1277–1280.
   PubMed Web of Science ®Google Scholar
• Pham DM, Subramanian R, Parekh S. Coexisting hepatopulmonary syndrome and portopulmonary hypertension: implications for liver transplantation. J Clin Gastroenterol. 2010;44:e136–e140.
   PubMed Web of Science ®Google Scholar
• Umeda A, Tagawa M, Kohsaka T, et al. Hepatopulmonary syndrome can show spontaneous resolution: possible mechanism of portopulmonary hypertension overlap? Respirology. 2006;11:120–123.
   PubMed Web of Science ®Google Scholar
• Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52:1355–1362.
   PubMed Web of Science ®Google Scholar
• Pellicelli AM. Cytokines in portopulmonary hypertension. Gut. 2004;53:1721.
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Barbaro G, Puoti C, et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology. 2010;61:802–806.
   PubMed Web of Science ®Google Scholar
• Sinzinger H. Prostacyclin in portopulmonary hypertension. Wien Klin Wochenschr. 2000;112:1020–1021.
   PubMed Web of Science ®Google Scholar
• Martinez-Palli G, Vidal JB, Beltran J, et al. Portopulmonary hypertension and hepatopulmonary syndrome: two different entities affecting pulmonary vasculature in liver disease. Crit Care Med. 2005;33:269.
   PubMed Web of Science ®Google Scholar
• Chavez-Tapia NC, Uribe M, Lopez E. Pulmonary complications of hepatic cirrhosis: portopulmonary hypertension and hepatopulmonary syndrome. The paradox of pulmonary vasoconstriction and vasodilation. Gac Med Mex. 2007;143:333–339.
   PubMed Web of Science ®Google Scholar
• Wong F. Portopulmonary hypertension in cirrhosis: the pathogenetic challenge. Gut. 2005;54:309.
   PubMed Web of Science ®Google Scholar
• Aldenkortt F, Aldenkortt M, Caviezel L, et al. Portopulmonary hypertension and hepatopulmonary syndrome. World J Gastroenterol. 2014;20:8072–8081.
   PubMed Web of Science ®Google Scholar
• Medarov BI, Chopra A, Judson MA. Clinical aspects of portopulmonary hypertension. Respir Med. 2014;108:943–954.
   PubMed Web of Science ®Google Scholar
• Bernthal AC, Eybel CE, Payne JA. Primary pulmonary hypertension after portocaval shunt. J Clin Gastroenterol. 1983;5:353–356.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Swanson KL, Krowka MJ, et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011;141:1673–1679.
   PubMed Web of Science ®Google Scholar
• Khimji AK, Rockey DC. Endothelin-biology and disease. Cell Signal. 2010;22:1615–1625.
   PubMed Web of Science ®Google Scholar
• Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res. 2011;63:504–511.
   PubMed Web of Science ®Google Scholar
• Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133–138.
   PubMed Web of Science ®Google Scholar
• Dupuis J. Endothelin-receptor antagonists in pulmonary hypertension. Lancet. 2001;358:1113–1114.
   PubMed Web of Science ®Google Scholar
• Halank M, Miehlke S, Hoeffken G, et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation. 2004;77:1775–1776.
   PubMed Web of Science ®Google Scholar
• Tempe DK, Datt V, Datta D. Bosentan for the treatment of portopulmonary hypertension. Ann Card Anaesth. 2008;11:139–140.
   PubMedGoogle Scholar
• Sallam M, Watson WC. Pulmonary hypertension due to micro-thromboembolism from splenic and portal veins after portacaval anastomosis. Br Heart J. 1970;32:269–271.
   PubMedGoogle Scholar
• Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol. 1987;10:1233–1238.
   PubMed Web of Science ®Google Scholar
• Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol. 1991;17:492–498.
   PubMed Web of Science ®Google Scholar
• Robbins IM, Kawut SM, Yung D, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;27:578–584.
   PubMed Web of Science ®Google Scholar
• Nakonechnicov S, Gabbasov Z, Chazova I, et al. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinolysis. 1996;7:225–227.
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70–75.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Ohsaki K, Shimoda S, et al. Thromboxane-dependent portopulmonary hypertension. Am J Med. 2005;118:93–94.
   PubMed Web of Science ®Google Scholar
• Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–842.
   PubMed Web of Science ®Google Scholar
• Girerd B, Coulet F, Jais X, et al. Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. Chest. 2015;147:1385–1394.
   PubMed Web of Science ®Google Scholar
• Maruyama H, Dewachter C, Belhaj A, et al. Endothelin-bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension. J Heart Lung Transplant. 2015;34:468–478.
   PubMed Web of Science ®Google Scholar
• Kabata H, Satoh T, Kataoka M, et al. Bone morphogenetic protein receptor type 2 mutations, clinical phenotypes and outcomes of Japanese patients with sporadic or familial pulmonary hypertension. Respirology. 2013;18:1076–1082.
   PubMed Web of Science ®Google Scholar
• Castano G, Sookoian S. Female sex and autoimmune hepatitis and the risk of portopulmonary hypertension. Hepatology. 2008;48:2090.
   PubMed Web of Science ®Google Scholar
• Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178:637–643.
   PubMed Web of Science ®Google Scholar
• Pilatis ND, Jacobs LE, Rerkpattanapipat P, et al. Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl. 2000;6:85–91.
   PubMed Web of Science ®Google Scholar
• Halank M, Langner S, Kolditz M, et al. Nocturnal oxygen desaturation is a frequent complication in portopulmonary hypertension. Z Gastroenterol. 2008;46:1260–1265.
   PubMed Web of Science ®Google Scholar
• Devaraj A, Loveridge R, Bosanac D, et al. Portopulmonary hypertension: improved detection using CT and echocardiography in combination. Eur Radiol. 2014;24:2385–2393.
   PubMed Web of Science ®Google Scholar
• Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453–458.
   PubMed Web of Science ®Google Scholar
• Torregrosa M, Genesca J, Gonzalez A, et al. Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation. 2001;71:572–574.
   PubMed Web of Science ®Google Scholar
• Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. Hepatobiliary Pancreat Dis Int. 2009;8:157–161.
   PubMed Web of Science ®Google Scholar
• Auletta M, Oliviero U, Iasiuolo L, et al. Pulmonary hypertension associated with liver cirrhosis: an echocardiographic study. Angiology. 2000;51:1013–1020.
   PubMed Web of Science ®Google Scholar
• Ko JM, Ahn MI, Han DH, et al. Dynamic CT and MRA findings of a case of portopulmonary venous anastomosis (PPVA) in a patient with portal hypertension: a case report and review of the literature. Acta Radiol. 2011;52:566–569.
   PubMed Web of Science ®Google Scholar
• Krowka MJ. Portopulmonary hypertension: diagnostic advances and caveats. Liver Transpl. 2003;9:1336–1337.
   PubMed Web of Science ®Google Scholar
• Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl. 2005;11:1107–1111.
   PubMed Web of Science ®Google Scholar
• Naeije R, Vachiery JL, Yerly P, et al. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J. 2013;41:217–223.
   PubMed Web of Science ®Google Scholar
• Porres-Aguilar M, Mukherjee D. Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: a redefinition to consider. Hepatology. 2015;61:733–734.
   PubMed Web of Science ®Google Scholar
• Krowka MJ. Portopulmonary hypertension and the issue of survival. Liver Transpl. 2005;11:1026–1027.
   PubMed Web of Science ®Google Scholar
• Saner FH, Nadalin S, Pavlakovic G, et al. Portopulmonary hypertension in the early phase following liver transplantation. Transplantation. 2006;82:887–891.
   PubMed Web of Science ®Google Scholar
• Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445–2453.
   PubMed Web of Science ®Google Scholar
• Porres-Aguilar M, Altamirano JT, Torre-Delgadillo A, et al. Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview. Eur Respir Rev. 2012;21:223–233.
   PubMedGoogle Scholar
• Savale L, O'Callaghan DS, Magnier R, et al. Current management approaches to portopulmonary hypertension. Int J Clin Pract Suppl. 2011;169:11–18.
   PubMedGoogle Scholar
• Chan-Dominy AC, Rahiman SN, Anders M, et al. Extracorporeal membrane oxygenation and severe portopulmonary hypertension following liver transplantation: brief report. Int J Artif Organs. 2015;38:337–342.
   PubMed Web of Science ®Google Scholar
• Solik P, Lesny P, Luknar M, et al. The long-term response to treatment with calcium channel blockers in a patient with idiopathic pulmonary arterial hypertension. Bratisl Lek Listy. 2013;114:283–286.
   PubMed Web of Science ®Google Scholar
• Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31:1898–1907.
   PubMed Web of Science ®Google Scholar
• Ota K, Shijo H, Kokawa H, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol. 1995;10:198–204.
   PubMed Web of Science ®Google Scholar
• Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–126.
   PubMed Web of Science ®Google Scholar
• Huonker M, Schumacher YO, Ochs A, et al. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut. 1999;44:743–748.
   PubMed Web of Science ®Google Scholar
• Van der Linden P, Le Moine O, Ghysels M, et al. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology. 1996;23:982–987.
   PubMed Web of Science ®Google Scholar
• DuBrock HM, Channick RN, Krowka MJ. What's new in the treatment of portopulmonary hypertension? Expert Rev Gastroenterol Hepatol. 2015;9:983–992.
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425–1436.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–340.
   PubMed Web of Science ®Google Scholar
• Greig SL, Scott LJ, Plosker GL. Epoprostenol (Veletri®, Caripul®): a review of its use in patients with pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2014;14:463–470.
   PubMed Web of Science ®Google Scholar
• Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104:9–21.
   PubMed Web of Science ®Google Scholar
• Safdar Z. Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs. Respir Med. 2011;105:818–827.
   PubMed Web of Science ®Google Scholar
• LeVarge BL. Prostanoid therapies in the management of pulmonary arterial hypertension. Ther Clin Risk Manag. 2015;11:535–547.
   PubMed Web of Science ®Google Scholar
• Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015;24:630–641.
   PubMedGoogle Scholar
• Saito Y, Nakamura K, Akagi S, et al. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2015;11:265–270.
   PubMed Web of Science ®Google Scholar
• Patel BB, Feng Y, Cheng-Lai A. Pulmonary arterial hypertension: a review in pharmacotherapy. Cardiol Rev. 2015;23:33–51.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30:641–648.
   PubMed Web of Science ®Google Scholar
• Sussman N, Kaza V, Barshes N, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant. 2006;6:2177–2182.
   PubMed Web of Science ®Google Scholar
• Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl. 2007;13:875–885.
   PubMed Web of Science ®Google Scholar
• Awdish RL, Cajigas HR. Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience. Lung. 2013;191:593–600.
   PubMed Web of Science ®Google Scholar
• Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation. 1998;65:457–459.
   PubMed Web of Science ®Google Scholar
• Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg. 1999;5:362–365.
   PubMedGoogle Scholar
• Touma W, Nayak RP, Hussain Z, et al. Epoprostenol-induced hypersplenism in portopulmonary hypertension. Am J Med Sci. 2012;344:345–349.
   PubMed Web of Science ®Google Scholar
• Clapp LH, Gurung R. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: role of membrane versus nuclear receptors. Prostaglandins Other Lipid Mediat. 2015;120:56–71.
   PubMed Web of Science ®Google Scholar
• Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J. 2004;24:703–707.
   PubMed Web of Science ®Google Scholar
• Molnar C, Alber H, Colleselli D, et al. Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis. Wien Klin Wochenschr. 2004;116:627–630.
   PubMed Web of Science ®Google Scholar
• Halank M, Marx C, Miehlke S, et al. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol. 2004;39:1222–1223.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J. 2007;30:1096–1102.
   PubMed Web of Science ®Google Scholar
• Melgosa MT, Ricci GL, Garcia-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl. 2010;16:348–356.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Shin MS, Oh KY, et al. Successful management of portopulmonary hypertension with beraprost. Eur J Gastroenterol Hepatol. 2010;22:1503–1505.
   PubMed Web of Science ®Google Scholar
• Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11:13–25.
   PubMedGoogle Scholar
• Pugliese SC, Bull TM. Clinical use of extended-release oral treprostinil in the treatment of pulmonary arterial hypertension. Integr Blood Press Control. 2016;9:1–7.
   PubMedGoogle Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142:1383–1390.
   PubMed Web of Science ®Google Scholar
• Tapson VF, Jing ZC, Xu KF, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144:952–958.
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127:624–633.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Selexipag: first global approval. Drugs. 2016;76:413–418.
   PubMed Web of Science ®Google Scholar
• O'Connell C, Amar D, Boucly A, et al. Comparative safety and tolerability of prostacyclins in pulmonary hypertension. Drug Saf. 2016. [Epub ahead of print]. doi: 10.1007/s40264-015-0365-x.
   PubMed Web of Science ®Google Scholar
• Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest. 2006;36 Suppl:54–61.
   Web of Science ®Google Scholar
• Maguire JJ, Davenport AP. Endothelin receptors and their antagonists. Semin Nephrol. 2015;35:125–136.
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Emoto N. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension. Ther Adv Cardiovasc Dis. 2014;8:202–216.
   PubMedGoogle Scholar
• Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502–508.
   PubMed Web of Science ®Google Scholar
• Grander W, Eller P, Fuschelberger R, et al. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest. 2006;36 Suppl:67–70.
   Web of Science ®Google Scholar
• Barth F, Gerber PJ, Reichen J, et al. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol. 2006;18:1117–1119.
   PubMed Web of Science ®Google Scholar
• Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J. 2013;41:96–103.
   PubMed Web of Science ®Google Scholar
• Austin MJ, McDougall NI, Wendon JA, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl. 2008;14:287–291.
   PubMed Web of Science ®Google Scholar
• Halank M, Kolditz M, Miehlke S, et al. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wien Med Wochenschr. 2005;155:376–380.
   PubMedGoogle Scholar
• Eriksson C, Gustavsson A, Kronvall T, et al. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis. 2011;20:77–80.
   PubMed Web of Science ®Google Scholar
• Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60–D72.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139:109–114.
   PubMed Web of Science ®Google Scholar
• Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol. 2011;49:1258–1262.
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736–745.
   PubMed Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818.
   PubMed Web of Science ®Google Scholar
• Cockrill BA, Waxman AB. Phosphodiesterase-5 inhibitors. Handb Exp Pharmacol. 2013;218:229–255.
   PubMedGoogle Scholar
• Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28:563–567.
   PubMed Web of Science ®Google Scholar
• Gough MS, White RJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl. 2009;15:30–36.
   PubMed Web of Science ®Google Scholar
• Hemnes AR, Robbins IM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl. 2009;15:15–19.
   PubMed Web of Science ®Google Scholar
• Fisher JH, Johnson SR, Chau C, et al. Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension. Can Respir J. 2015;22:42–46.
   PubMed Web of Science ®Google Scholar
• Hollatz TJ, Musat A, Westphal S, et al. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl. 2012;18:686–695.
   PubMed Web of Science ®Google Scholar
• Wang RC, Jiang FM, Zheng QL, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med. 2014;108:531–537.
   PubMed Web of Science ®Google Scholar
• Yoshida EM, Erb SR, Pflugfelder PW, et al. Single-lung versus liver transplantation for the treatment of portopulmonary hypertension – a comparison of two patients. Transplantation. 1993;55:688–690.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:443–450.
   PubMed Web of Science ®Google Scholar
• Martin P, DiMartini A, Feng S, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–1165.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10:174–182.
   PubMed Web of Science ®Google Scholar
• Khaderi S, Khan R, Safdar Z, et al. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl. 2014;20:724–727.
   PubMed Web of Science ®Google Scholar
• Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant. 2007;7:1258–1264.
   PubMed Web of Science ®Google Scholar
• Goldberg DS, Batra S, Sahay S, et al. MELD exceptions for portopulmonary hypertension: current policy and future implementation. Am J Transplant. 2014;14:2081–2087.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Fallon MB, Mulligan DC, et al. Model for end-stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl. 2006;12:S114–S116.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Wiesner RH, Heimbach JK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol. 2013;59:367–374.
   PubMed Web of Science ®Google Scholar
• Pirenne J, Verleden G, Nevens F, et al. Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation. 2002;73:140–142.
   PubMed Web of Science ®Google Scholar
• Grannas G, Neipp M, Hoeper MM, et al. Indications for and outcomes after combined lung and liver transplantation: a single-center experience on 13 consecutive cases. Transplantation. 2008;85:524–531.
   PubMed Web of Science ®Google Scholar